Dishman dumps project to raise cash; Bedford recalls more products; Goldman invests in Orchid;

> Beleaguered Bedford Laboratories issued recall of a lot of Vecuronium Bromide after its was discovered some vials contain particulates. FDA announcement

> Goldman Sachs has acquired about a 1% stake in API maker Orchid Chemicals, paying Rs86m ($1.51 million) for 742,001 shares. Item

> With the results of an arrhythmia safety study in, the FDA is having GlaxoSmithKline ($GSK) expand the labeling changes on its Zofran, which is used in chemotherapy for vomiting and nausea. Story

> Ampio Pharmaceuticals, has contracted with Syngene in Bangalore, India, to begin manufacturing the products it now has in clinical trials. Release

> Survey finds increase in single-use technology for fill and finish. Story

> Standard Process is recalling its dietary supplements Cataplex ACP, Cataplex C and Pancreatrophin PMG, which are generally provided through doctors, after a routine inspection by the FDA discovered one of the ingredients in them may be contaminated with salmonella. FDA alert

And Finally... Dishman Pharmaceuticals is dumping its 6-year-old Special Economic Zone project near Ahmedabad, India, and will sell the land and use the proceeds to pay off debt. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.